Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	385.69	270.6	50.04	-	-
Revenue Growth (YoY)	42.53%	440.80%	-	-	-
Cost of Revenue	33.3	26.07	4.1	-	-
Gross Profit	352.39	244.54	45.94	-	-
Selling, General & Admin	411.36	323.12	159.25	66.65	28.9
Research & Development	187.08	97.94	57.95	58.06	70.19
Operating Expenses	604.83	427.44	221.34	124.71	99.09
Operating Income	-252.44	-182.91	-175.4	-124.71	-99.09
Interest Expense	-6.57	-6.45	-7.34	-5.7	-2.57
EBT Excluding Unusual Items	-259.01	-189.36	-182.74	-130.4	-101.65
Merger & Restructuring Charges	-	-	-1.1	-	-
Other Unusual Items	-28.12	-48.92	-3.3	-	-1.25
Pretax Income	-287.13	-238.28	-187.13	-130.4	-102.9
Income Tax Expense	0.09	0.96	-	-	-
Net Income	-287.22	-239.24	-187.13	-130.4	-102.9
Net Income to Common	-287.22	-239.24	-187.13	-130.4	-102.9
Shares Outstanding (Basic)	48	45	41	38	37
Shares Outstanding (Diluted)	48	45	41	38	37
Shares Change (YoY)	5.48%	11.73%	8.07%	1.11%	9.37%
EPS (Basic)	-5.99	-5.27	-4.60	-3.47	-2.77
EPS (Diluted)	-5.99	-5.27	-4.60	-3.47	-2.77
Free Cash Flow	-128.68	-145.66	-117.21	-108.53	-78.5
Free Cash Flow Per Share	-2.69	-3.21	-2.88	-2.88	-2.11
Gross Margin	91.36%	90.37%	91.81%	-	-
Operating Margin	-65.45%	-67.59%	-350.54%	-	-
Profit Margin	-74.47%	-88.41%	-373.99%	-	-
Free Cash Flow Margin	-33.36%	-53.83%	-234.25%	-	-
EBITDA	-244.48	-176.07	-171	-124.63	-99.06
EBITDA Margin	-63.39%	-65.07%	-	-	-
D&A For EBITDA	7.96	6.83	4.4	0.08	0.02
EBIT	-252.44	-182.91	-175.4	-124.71	-99.09
EBIT Margin	-65.45%	-67.59%	-	-	-
Revenue as Reported	385.69	270.6	50.04	-	-
Advertising Expenses	101.2	100.3	35.3	-	-

Updated Feb 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q